| Dr Christopher David Correa, DPM | |
|
25222 Northwest Fwy Apt 185, Cypress, TX 77429-1038 | |
| (832) 743-0508 | |
| (832) 743-0588 |
| Full Name | Dr Christopher David Correa |
|---|---|
| Gender | Male |
| Speciality | Podiatry |
| Experience | 12 Years |
| Location | 25222 Northwest Fwy Apt 185, Cypress, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013263946 | NPI | - | NPPES |
| 8MT028 | Other | TX | BLUE CROSS AND BLUE SHIELD |
| 346947003 | Medicaid | TX | |
| 7854240001 | Other | TX | DME LICENSE NUMBER |
| P02482063 | Other | TX | RAIL ROAD MEDICARE |
| 2456064 | Other | TX | WELLCARE ID |
| 1C9075 | Other | TX | MEDICARE NUMBER |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213E00000X | Podiatrist | 2145 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Memorial Hermann - Texas Medical Center | Houston, TX | Hospital |
| Provider Name | Emergency Hospital Systems Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1992172019 PECOS PAC ID: 2567765761 Enrollment ID: O20170607000131 |
News Archive
The Global Health Innovative Technology Fund (GHIT Fund), a new public health partnership that is bringing Japanese know-how and investment to the global fight against infectious diseases, announced today grants of US$5.7 million to six global partnerships working on innovative drugs and vaccines against malaria, tuberculosis and Chagas disease.
The April issue of the WHO Bulletin features an editorial on the WHO research agenda for influenza; a public health round-up; an article on influenza in Ghana; a research paper on population-based burden of influenza-associated hospitalization in rural western Kenya; and a policy paper on the integration of pneumonia prevention and treatment interventions with immunization services in resource-poor countries.
Using a drug-discovery technique in which molecules compete against each other for access to the target - the strand of toxic RNA that causes the most common form of muscular dystrophy in adults - a team at the University of Rochester Medical Center has identified several compounds that, in the laboratory, block the unwanted coupling of two molecules that is at the root of the disease.
PAREXEL International Corporation, a leading global biopharmaceutical services provider, announced today that it has achieved a significant milestone by completing its 100th Asian ethnobridging study, which is designed to help biopharmaceutical companies accelerate development for the Asia/Pacific market.
The U.S. Food and Drug Administration (FDA) today approved an innovative combination of technologies that will enhance a doctors' ability to treat patients with abnormal heart rhythms (cardiac arrhythmias).
› Verified 6 days ago
| Provider Name | Select Foot And Ankle Specialists, P.l.l.c. |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1013536952 PECOS PAC ID: 1355762212 Enrollment ID: O20200601001197 |
News Archive
The Global Health Innovative Technology Fund (GHIT Fund), a new public health partnership that is bringing Japanese know-how and investment to the global fight against infectious diseases, announced today grants of US$5.7 million to six global partnerships working on innovative drugs and vaccines against malaria, tuberculosis and Chagas disease.
The April issue of the WHO Bulletin features an editorial on the WHO research agenda for influenza; a public health round-up; an article on influenza in Ghana; a research paper on population-based burden of influenza-associated hospitalization in rural western Kenya; and a policy paper on the integration of pneumonia prevention and treatment interventions with immunization services in resource-poor countries.
Using a drug-discovery technique in which molecules compete against each other for access to the target - the strand of toxic RNA that causes the most common form of muscular dystrophy in adults - a team at the University of Rochester Medical Center has identified several compounds that, in the laboratory, block the unwanted coupling of two molecules that is at the root of the disease.
PAREXEL International Corporation, a leading global biopharmaceutical services provider, announced today that it has achieved a significant milestone by completing its 100th Asian ethnobridging study, which is designed to help biopharmaceutical companies accelerate development for the Asia/Pacific market.
The U.S. Food and Drug Administration (FDA) today approved an innovative combination of technologies that will enhance a doctors' ability to treat patients with abnormal heart rhythms (cardiac arrhythmias).
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Christopher David Correa, DPM 14502 Cypress Mill Place Blvd Ste 200, Cypress, TX 77429-7300 Ph: (832) 743-0508 | Dr Christopher David Correa, DPM 25222 Northwest Fwy Apt 185, Cypress, TX 77429-1038 Ph: (832) 743-0508 |
News Archive
The Global Health Innovative Technology Fund (GHIT Fund), a new public health partnership that is bringing Japanese know-how and investment to the global fight against infectious diseases, announced today grants of US$5.7 million to six global partnerships working on innovative drugs and vaccines against malaria, tuberculosis and Chagas disease.
The April issue of the WHO Bulletin features an editorial on the WHO research agenda for influenza; a public health round-up; an article on influenza in Ghana; a research paper on population-based burden of influenza-associated hospitalization in rural western Kenya; and a policy paper on the integration of pneumonia prevention and treatment interventions with immunization services in resource-poor countries.
Using a drug-discovery technique in which molecules compete against each other for access to the target - the strand of toxic RNA that causes the most common form of muscular dystrophy in adults - a team at the University of Rochester Medical Center has identified several compounds that, in the laboratory, block the unwanted coupling of two molecules that is at the root of the disease.
PAREXEL International Corporation, a leading global biopharmaceutical services provider, announced today that it has achieved a significant milestone by completing its 100th Asian ethnobridging study, which is designed to help biopharmaceutical companies accelerate development for the Asia/Pacific market.
The U.S. Food and Drug Administration (FDA) today approved an innovative combination of technologies that will enhance a doctors' ability to treat patients with abnormal heart rhythms (cardiac arrhythmias).
› Verified 6 days ago
Select Foot And Ankle Specialists Podiatrist Medicare: Medicare Enrolled Practice Location: 14502 Cypress Mill Place Blvd Ste 200, Cypress, TX 77429 Phone: 832-743-0508 Fax: 832-743-0588 | |
Cypress Foot And Ankle Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 21212 Northwest Fwy, Suite 215, Cypress, TX 77429 Phone: 281-596-7224 | |
Steven J Stanton, Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 9740 Barker Cypress Rd Ste 108b, Cypress, TX 77433 Phone: 281-550-3338 Fax: 281-550-3436 | |
The Frazier Foot And Ankle Center Podiatrist Medicare: Medicare Enrolled Practice Location: 12609 Louetta Rd Ste B, Cypress, TX 77429 Phone: 281-720-8267 Fax: 281-845-2554 | |
Dr. Meynard Morrie Nussbaum, D.P.M. Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 9740 Barker Cypress Rd, Ste 108b, Cypress, TX 77433 Phone: 832-781-2690 Fax: 832-409-3169 | |
Foot Wellness Center Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 21216 Northwest Fwy Ste 240, Cypress, TX 77429 Phone: 281-955-5500 Fax: 281-890-9365 |